Photocure divests Metvix? to Galderma for EUR 51 million

01-01-2011 11:11

With reference to the stock exchange notification regarding Photocure’s divestment of Metvix? to Galderma today, Thursday 1 October 2009, Photocure is hereby inviting to a press and analyst conference to present the transaction in more detail.
The presentation will take place today, at 01.00 pm at Shippingklubben, Haakon VIIs gate 1 (top floor), Oslo, Norway. Lunch will be served.
The presentation will be made by Kjetil Hestdal, President and CEO.
Best regards,
Christian Fekete, CFO
E-mail: [email protected]
Mobile: +47 916 42 938
Office: +47 22 06 22 10
About Photocure
Photocure is a Norwegian pharmaceutical company listed on the Oslo Stock Exchange (OSE: PHO). The company develops and sells pharmaceuticals and medical devices for the photodynamic treatment and diagnosis of cancer and selected dermatology indications.
Photocure’s commercial activities includes own marketing and sales in selected markets as well as out-licensing to leading pharmaceutical companies on a regional or global basis prior to phase III.
Photocure has one proprietary pharmaceutical product on the market: Hexvix?, for the diagnosis of bladder cancer. Hexvix is approved in EU and under priority review by FDA in the US. In addition, the company has developed a proprietary light source, which is used in combination with the Visonac(TM) cream. Through worldwide studies, Photocure is continuously testing its products for new indications, and the aim is to develop a pipeline of follow-on products based on the Photocure Technology(TM) platform.
For more information about Photocure, visit our website at

A to już wiesz?  PRESSINBJUDAN: Välkommen till invigning av nya Barnakuten

Artykuly o tym samym temacie, podobne tematy